The medium-sized biopharma is showing off new results from dordaviprone and Zepzelca, both of which were acquired through ...

Despite mixed results, analysts maintained faith in ivonescimab’s ability to cross over between Eastern and Western patient ...

Keros will be down to 85 full-time employees after the layoffs and expects to generate annualized savings of $17 million.

At the heart of the deal is an anti-Claudin18.2 antibody-drug conjugate being developed for solid tumors, including gastric ...

Although the FDA has rejected Stealth’s new drug application for Barth syndrome candidate elamipretide, the agency identified ...

According to the nonprofit news outlet NOTUS, at least seven studies cited in the Make America Healthy Again report released ...

The National Legal and Policy Center, a right-wing advocacy and watchdog group, had asked the company to revisit its DEI ...

Analysts at Truist Securities admitted that the result for itepekimab, which the companies were hoping to follow their ...

Nearly a third of employed and almost half of unemployed BioSpace survey respondents are seriously considering leaving the ...

Patritumab deruxtecan was unable to significantly improve overall survival in patients with locally advanced or metastatic ...

While an adverse event reported in Intellia’s gene therapy trial was a “non-concern” for analysts, it follows a handful of ...

According to President Trump, CMS Administrator Mehmet Oz is a “tough hombre” who can bring down drug costs “like a rock.” ...